ALASKA MEDICAID
Prior Authorization Criteria

Oxbryta™ (voxelotor)

FDA INDICATIONS AND USAGE[1]

Oxbryta™ is indicated to treat sickle cell disease in patients 4 years of age and older. It is a hemoglobin S polymerization inhibitor that was approve under the accelerated pathway. The drug is thought to inhibit red blood cell sickling, improve red blood cell deformity, and reduce whole blood viscosity.

APPROVAL CRITERIA[1,2]

1. Patient is 4 years of age or older AND;
2. Patient has the diagnosis of sickle cell disease AND;
3. Prescribed by or consultation with a hematologist or a provider that specializes in sickle cell disease AND;
4. Documentation that the patient has had at least one vaso-occlusive crisis within the past 6 months AND;
5. Has a documented baseline hemoglobin AND;
6. Patient has tried and failed or has a contraindication to hydroxyurea for at least 3 months.

DENIAL CRITERIA[1,2]

1. Failure to meet approval criteria OR;
2. Patient is receiving concomitant, prophylactic blood transfusions OR;
3. Concomitantly being prescribed with Adakveo.

CAUTIONS[1]

- Concomitant use of moderate to strong CYP3A4 inhibitors should be avoided.
- Monitor for hypersensitivity reactions and manage promptly.

DURATION OF APPROVAL

- Approval: Up to 3 months
- Reauthorization: Up to 12 months with documentation showing an increase in hemoglobin and/or decrease in vaso-occlusive crisis related emergencies.

QUANTITY LIMITS

- 90 – 500mg tablets per 30 days
- 90 – 300mg tablets for oral suspension

REFERENCES / FOOTNOTES:

1. Oxbryta™ [prescribing information]. San Francisco, CA: Global Blood Therapeutics; November 2019.
2. Brown C, Hoppe C, Inati A, et al. Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease. Blood:132(Suppl 1):509. Accessed November 26, 2019.